Allworth Financial’s Citius Pharmaceuticals CTXR Stock Holding History

Allworth Financial’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12	Closed	-$151	–	3964
2024 Q3	$151	Buy	+12	New	+$202	﹤0.01%	3635

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Allworth Financial's CTXR Position: Q4 2024 in Review

Allworth Financial sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 12 shares — an estimated $151 sold.

Allworth Financial first reported a position in CTXR in Q3 2024 and held it in 1 quarter. The position peaked at $151 in Q3 2024. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

Allworth Financial reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Allworth Financial sold 12 Citius Pharmaceuticals shares in Q4 2024, an estimated $151.
Allworth Financial first reported a position in Citius Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Allworth Financial's Citius Pharmaceuticals position peaked at $151 in Q3 2024.
30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Allworth Financial's 13F filing for Q4 2024, filed 30 Jan 2025.